NextCure, Inc.
No enriched coverage for $NXTC in the last 7 days.
No SEC Form 4 filings for $NXTC in the last 30 days.
BELTSVILLE, Md., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( NASDAQ:NXTC ) , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat ...
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( Nasdaq: NXTC ) , a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere ...
